‘The pink ribbon is arguably the most successful marketing tool of the 20th century.’ — Karuna Jaggar, Breast Cancer Action (Getty Images)
You may have read the other day about the big Stanford study on double mastectomies. Researchers looked at outcomes for every women in California diagnosed with early-stage breast cancer from 1998 to 2011 — – all 189,734 of them — and found, surprisingly, that removing both breasts doesn’t increase breast cancer survival rate.
Women who had breast-conserving surgery had an 83.2 percent survival rate at 10 years, compared with 81.2 percent for those who had a double mastectomy.
“What it means is that women should be aware that if they choose double mastectomy, the chances are that it won’t cause them to live any longer than if they had chosen something else,” said Stanford professor Allison Kurian, lead author of the study.
Perhaps even more surprising than the lack of evidence to recommend double mastectomies is the discovery that, from 1998 to 2011, the procedure had risen among the large population studied from 2 percent to 12 percent. And for women under 40, the rate increased from 3.6 percent to a whopping 33 percent, “even though most of them had stage zero or stage one cancer, a very early, very treatable form,” NPR reports.
About one-third of women under 40 diagnosed with breast cancer in California choose double mastectomy. (Getty Images)
By Nancy Shute, NPR
More women are choosing to have bilateral mastectomies when they are diagnosed with early-stage breast cancer, even though there’s little evidence that removing both breasts improves their survival compared with more conservative treatments.
Doctors worry that women choose double mastectomy out of the mistaken belief that it eliminates their future risk of cancer.
The biggest study yet on the question has found no survival benefit with bilateral mastectomy compared to breast-conserving surgery with radiation.
The study, published Tuesday in JAMA, the Journal of the American Medical Association, looked at the records of all women in California who were diagnosed with early-stage breast cancer from 1998 to 2011 — 189,734 women, all told. Continue reading
By Nancy Shute, NPR
The number of women getting double mastectomies after a breast cancer diagnosis has been rising in the past 10 years, even though most of them don’t face a higher risk of getting cancer in the other breast.
More than two-thirds of the women who had the double mastectomy had no risk factors that would make it more likely that they would get breast cancer again.
That has cancer doctors troubled, because for those women having the other breast removed doesn’t reduce their risk of getting breast cancer again or increase their odds of survival. And they don’t know why women are making this choice.
Worry about the cancer coming back is one of the biggest reasons, according to a study of women in California and Michigan that tried to figure out which women decided on a double mastectomy, and why.
Women who had a breast MRI were more likely to decide on a double mastectomy, even if the scan didn’t show more cancer. Continue reading
Women who exercised an hour a day saw the greatest risk reduction, but women who weren’t as active also reduced their risk. (Getty Images)
By Nancy Shute, NPR
This could be the simplest bit of health advice ever: Exercise reduces women’s risk of breast cancer, no matter what kind of exercise they do, how old they are, how much they weigh, or when they get started.
The more active a woman is, the better her odds of avoiding breast cancer.
Researchers in France looked at studies that involved more than 4 million women around the world who participated in prospective studies from 1987 to 2013. They found that the more active a woman is, the better her odds of avoiding breast cancer. Women who were most active, with more than an hour a day of vigorous activity, got the most benefits, lowering their cancer risk by 12 percent.
But women who weren’t as active saw reduced risk, too, notes Mathieu Boniol, research director at the Strathclyde Institute for Global Public Health in Lyon, France. More activity was better, but anything was better than nothing. He presented the data Thursday at the European Breast Cancer Conference in Glasgow. Continue reading
More evidence is in this week that casts doubt on the value of mammograms. To recap: Canadian researchers followed nearly 90-thousand women since the 1980s. The women were randomly assigned to mammography or physical breast exam. Now 25 years later, the researchers say that roughly equal numbers of women in each group died of breast cancer — mammography, according to this study, is not affecting the death rate at all.
In addition, mammography comes with harms. More than 1 in 5 cancers found in the mammography group were not ones that pose a threat to women’s health, the researchers say. Doctors call this “overdiagnosis.” This is a problem because the treatments for cancer are aggressive — surgery, radiation therapy, chemotherapy — and can cause harms in and of themselves. “There is no question that there is an excess in the diagnosis of tumors that are not going to kill you,” Dr. Laura Esserman, head of the UC San Francisco breast care center, told me, “We all know this phenomenon exists, but this quantifies it.”
Those are the headlines. Thursday morning, KQED’s Forum got into more detail. I was particularly interested in two points the guests made. The first was about new approaches to screening and the second was about screening as distinguished from prevention. Continue reading
The issue of how often a woman should be screened for breast cancer has been a topic of hot debate for years. But of the many different issues that are closely examined, cost is rarely among them.
Even mentioning cost typically gets patients somewhat understandably up in arms — no one wants her life to be determined by mere dollars.
But what if those dollars are being spent poorly? The harms of mammograms are well-known — false positives and overtreatment among them. What if reconsidering what we’re doing and how we’re doing it could actually lead to more lives saved?
Into the fray comes an analysis from several researchers, including Dr. Laura Esserman, a breast cancer surgeon with UCSF. They calculated the costs for screening mammography in the U.S. under different scenarios. Continue reading
(Go Interactive Wellness/Flickr)
By Allison Aubrey, NPR
Exercise helps recovery after cancer treatment, but fatigue can make working out hard. Yoga can help reduce fatigue for breast cancer survivors, a study finds. It’s one of a growing number of efforts using randomized controlled trials to see if the ancient practice offers medical benefits.
Women who took a yoga class three hours a week for three months said they experienced 40 percent less fatigue compared to a group of breast cancer survivors who did not do yoga.
“Fatigue is a major and serious problem in survivors,” even years after treatments have ended, Janice Kiecolt-Glaser, a psychology professor at Ohio State University and lead author of the study, said.
The participants who did yoga also had lower levels of cytokines, which are markers of inflammation, in their blood, Kiecolt-Glaser says. Cytokine levels were reduced up to 20 percent six months after starting yoga. It’s not clear how this may affect their health, she says. Continue reading
Retailer J.C. Penney features a Girls Plus clothing department tailored to overweight girls. (Scott Olson/Getty Images)
Building on earlier research a major new study has found that girls are starting puberty at even younger ages. The most significant changes were seen in Caucasian girls and in girls who are overweight or obese. Still, girls who were not overweight were also entering puberty younger, the study found.
Researchers at three sites around the country — including the San Francisco Bay Area — followed 1,239 ethnically diverse girls from 2004 to 2011. They looked at breast development, a key marker for the start of puberty.
Girls who mature earlier are at risk for lower self-esteem and higher rates of depression.
Earlier studies had shown that African-American girls had reached this milestone at younger ages. “Now it looks like it’s happening earlier for Caucasian girls,” said Dr. Louise Greenspan, a pediatric endocrinologist with Kaiser San Francisco and one of the authors of the study. “Particularly, the overweight Caucasian girls are developing earlier than they have in the past.”
Researchers looked at a number of factors, but the “obesity epidemic appears to be a prime driver in the decrease in age at onset of breast development,” the authors wrote. Continue reading
By Patti Neighmond and Richard Knox, NPR
Peggy MacDonald of Portland, Ore., chose not to have surgery for DCIS.
When Sally O’Neill’s doctor told her she had an early form of cancer in one of her breasts, she didn’t agonize about what she wanted to.
The 42-year-old mother of two young girls wanted a double mastectomy.
In many cases it doesn’t ever progress to invasive cancer, the type that can be life-threatening.
“I decided at that moment that I wanted them both taken off,” says O’Neill, who lives in a suburb of Boston. “There wasn’t a real lot of thought process to it. I always thought, ‘If this happens to me, this is what I’m going to do.’ Because I’m not taking any chances. I want the best possible outcome. I don’t want to do a wait-and-see.”
Today, 10 years later, O’Neill has no regrets about what most people would consider a radical decision. And as it turns out, she was at the leading edge of a trend.
O’Neill had ductal carcinoma in situ, or DCIS. The number of women who get double mastectomies because of DCIS is small – around one in 16 women (see accompanying chart). But the rate has doubled in the past 10 years. Continue reading
(William West/AFP/Getty Images)
In a unanimous decision, the U.S. Supreme Court ruled Thursday morning that human genes are not patentable.
The case centered around Myriad Genetics, the holder of patents on two genes, BRCA1 and BRCA2. Some mutations of these genes are associated with an increased risk of breast and ovarian cancer. For women with a strong family history of these cancers, the only place they could be tested was Myriad Genetics, which sometimes charged more than $3,000 for the test.
Breast Cancer Action, an advocacy group based in San Francisco, was a plaintiff in the case, and executive director Karuna Jaggar sounded jubilant in a phone call Thursday morning.
“From our perspective, these patents never should have been granted in the first place,” Jaggar said. “There’s no question that DNA is a product of nature, and so it’s very affirming to see the court rule in our favor.”
BRCA1 and 2 mutations became international news when actress Angelina Jolie revealed that she’d had a preventive double mastectomy after testing showed that she had a specific mutation that put her at very high risk of developing breast cancer.